Dan Niculescu‐Duvaz

6.7k citations

35 papers · 4.1k indexed · 1 hit paper · h-index 21

Molecular Biology top 2%
Oncology top 2%
Pathology and Forensic Medicine top 2%
Computational Theory and Mathematics top 0.5%
Organic Chemistry top 5%

Co-authors: Caroline J. Springer Richard Marais Christopher J. Marshall David Barford Mathew J. Garnett Chris M. Jones Valerie M. Good Paul Wan
Topics: Melanoma and MAPK Pathways (18 papers)Virus-based gene therapy research (7 papers)Click Chemistry and Applications (6 papers)
Cited by: Oncology Molecular Biology Computational Theory and Mathematics
Journals: Cell Nature Communications Journal of Clinical Oncology
Partner nations: United Kingdom United States Switzerland

In The Last Decade

Dan Niculescu‐Duvaz

34 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

2004 2.2k citations Paul Wan, Mathew J. Garnett et al. Cell profile →

Peers

Countries citing papers authored by Dan Niculescu‐Duvaz

Since Specialization

Citations

This map shows the geographic impact of Dan Niculescu‐Duvaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dan Niculescu‐Duvaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dan Niculescu‐Duvaz more than expected).

Fields of papers citing papers by Dan Niculescu‐Duvaz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dan Niculescu‐Duvaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dan Niculescu‐Duvaz. The network helps show where Dan Niculescu‐Duvaz may publish in the future.

Co-authorship network of co-authors of Dan Niculescu‐Duvaz

This figure shows the co-authorship network connecting the top 25 collaborators of Dan Niculescu‐Duvaz. A scholar is included among the top collaborators of Dan Niculescu‐Duvaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dan Niculescu‐Duvaz. Dan Niculescu‐Duvaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hijacking the MDM2 E3 Ligase with Novel BRD4‐Targeting Proteolysis‐Targeting Chimeras in Pancreatic Cancer Cells 2025 ·ChemBioChem ·(unknown),Dan Niculescu‐Duvaz,(unknown),(unknown),Caroline J. Springer	2
2	2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth 2019 ·Journal of Medicinal Chemistry ·Deborah A. Smithen,(unknown),Mairi Challinor,(unknown),Haoran Tang,Dan Niculescu‐Duvaz,Simon P. Pearce,(unknown),Filipa M. Lopes,(unknown),Michael Brown,Louise D. Johnson,Graeme Thomson,Richard Marais,Caroline J. Springer	30
3	Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface 2017 ·Nature Communications ·Haoran Tang,(unknown),Grazia Saturno,Amaya Virós,Duncan L. Smith,Gianpiero Di Leva,(unknown),Dan Niculescu‐Duvaz,Filipa M. Lopes,Louise D. Johnson,Nathalie Dhomen,Caroline J. Springer,Richard Marais	73
4	Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents 2013 ·Bioorganic & Medicinal Chemistry ·Dan Niculescu‐Duvaz,Ion Niculescu‐Duvaz,Bart M. J. M. Suijkerbuijk,Delphine Ménard,Alfonso Zambon,Lawrence Davies,Jean‐François Pons,Steven R. Whittaker,Richard Marais,Caroline J. Springer	36
5	Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. 2013 ·Cancer Research ·María Romina Girotti,Malin Pedersen,Berta Sanchez‐Laorden,Amaya Virós,Samra Turajlic,Dan Niculescu‐Duvaz,Alfonso Zambon,John Sinclair,Andrew Hayes,Martin Gore,Caroline J. Springer,James Larkin,Claus Jørgensen,Richard Marais	1
6	BRAF as a therapeutic target: a patent review (2006 – 2012) 2013 ·Expert Opinion on Therapeutic Patents ·Alfonso Zambon,Dan Niculescu‐Duvaz,Ion Niculescu‐Duvaz,Richard Marais,Caroline J. Springer	10
7	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma 2012 ·Cancer Discovery ·María Romina Girotti,Malin Pedersen,Berta Sanchez‐Laorden,Amaya Virós,Samra Turajlic,Dan Niculescu‐Duvaz,Alfonso Zambon,John Sinclair,Andrew Hayes,Martin Gore,Paul Lorigan,Caroline J. Springer,James Larkin,Claus Jørgensen,Richard Marais	272
8	Small molecule inhibitors of BRAF in clinical trials 2011 ·Bioorganic & Medicinal Chemistry Letters ·Alfonso Zambon,Ion Niculescu‐Duvaz,Dan Niculescu‐Duvaz,Richard Marais,Caroline J. Springer	47
9	Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds 2010 ·Bioorganic & Medicinal Chemistry ·Dan Niculescu‐Duvaz,Ion Niculescu‐Duvaz,Bart M. J. M. Suijkerbuijk,Delphine Ménard,Alfonso Zambon,Arnaud Nourry,Lawrence Davies,(unknown),Frank Friedlos,Lesley Ogilvie,Douglas Hedley,Andrew K. Takle,David M. Wilson,Jean‐François Pons,(unknown),Richard Kirk,Neus Cantariño,Steven R. Whittaker,Richard Marais,Caroline J. Springer	28
10	BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle Ring 2010 ·Journal of Medicinal Chemistry ·Arnaud Nourry,Alfonso Zambon,Lawrence Davies,Ion Niculescu‐Duvaz,(unknown),Delphine Ménard,(unknown),Dan Niculescu‐Duvaz,Bart M. J. M. Suijkerbuijk,Frank Friedlos,(unknown),Richard Kirk,Steven R. Whittaker,Richard Marais,Caroline J. Springer	18
11	Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors 2010 ·Journal of Medicinal Chemistry ·Alfonso Zambon,Delphine Ménard,Bart M. J. M. Suijkerbuijk,Ion Niculescu‐Duvaz,Steven R. Whittaker,Dan Niculescu‐Duvaz,Arnaud Nourry,Lawrence Davies,(unknown),Filipa M. Lopes,Natasha Preece,Douglas Hedley,Lesley Ogilvie,Richard Kirk,Richard Marais,Caroline J. Springer	31
12	Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies 2010 ·Science Translational Medicine ·Steven R. Whittaker,Richard Kirk,Robert Hayward,Alfonso Zambon,Amaya Virós,Neus Cantariño,Annette Affolter,Arnaud Nourry,Dan Niculescu‐Duvaz,Caroline J. Springer,Richard Marais	118
13	A Facile Synthesis of an Oxazolo[5,4]pyrimidin-2-one and a Pyrimido[5,4][1,3]oxazin-2-one 2006 ·Synlett ·Caroline J. Springer,(unknown),(unknown),Dan Niculescu‐Duvaz	1
14	Design of Prodrugs for Suicide Gene Therapy 2004 ·Humana Press eBooks ·Dan Niculescu‐Duvaz,Ion Niculescu‐Duvaz,Caroline J. Springer	13
15	B-RAF is a therapeutic target in melanoma 2004 ·Oncogene ·Maria Karasarides,Antonio Chiloeches,Robert Hayward,Dan Niculescu‐Duvaz,Ian Scanlon,Frank Friedlos,Lesley Ogilvie,Douglas Hedley,Jan Martin,Christopher J. Marshall,Caroline J. Springer,Richard Marais	360
16	Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFbreakdown → 2004 ·Cell ·Paul Wan,Mathew J. Garnett,S. Mark Roe,(unknown),Dan Niculescu‐Duvaz,Valerie M. Good,(unknown),Chris M. Jones,Christopher J. Marshall,Caroline J. Springer,David Barford,Richard Marais	2174
17	Structure-Activity Relationship in Cationic Lipid Mediated Gene Transfection 2003 ·Current Medicinal Chemistry ·Dan Niculescu‐Duvaz,James Heyes,Caroline J. Springer	127
18	Self-Immolative Nitrogen Mustards Prodrugs Cleavable by Carboxypeptidase G2 (CPG2) Showing Large Cytotoxicity Differentials in GDEPT 2003 ·Journal of Medicinal Chemistry ·Dan Niculescu‐Duvaz,Ion Niculescu‐Duvaz,Frank Friedlos,(unknown),Panos Lehouritis,Richard Marais,Caroline J. Springer	19
19	Self-Immolative Anthracycline Prodrugs for Suicide Gene Therapy 1999 ·Journal of Medicinal Chemistry ·Ion Niculescu‐Duvaz,Dan Niculescu‐Duvaz,Frank Friedlos,Robert A. Spooner,Janet L. Martin,Richard Marais,Caroline J. Springer	32
20	Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). 1999 ·PubMed ·Ion Niculescu‐Duvaz,Frank Friedlos,Dan Niculescu‐Duvaz,Lawrence Davies,Caroline J. Springer	29

About Dan Niculescu‐Duvaz

Dan Niculescu‐Duvaz is a scholar working on Molecular Biology, Organic Chemistry and Immunology and Allergy, having authored 35 papers that have together received 4.1k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (18 papers), Virus-based gene therapy research (7 papers) and Click Chemistry and Applications (6 papers). The work is most often cited by research in Oncology (1.6k citations), Molecular Biology (3.3k citations) and Computational Theory and Mathematics (611 citations). Dan Niculescu‐Duvaz has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Caroline J. Springer, Richard Marais, Christopher J. Marshall, David Barford, Mathew J. Garnett, Chris M. Jones, Valerie M. Good, Paul Wan, S. Mark Roe and James Heyes. Their work appears in journals such as Cell, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact